Response to PI3K/mTOR dual inhibition in Glioma initiating cells

The PI3K/mammalian target of rapamycin (mTOR) pathway is dysregulated in over 50% of human GBM but remains a challenging clinical target. Inhibitors against PI3K/mTOR mediators have limited clinical efficacy as single agents. Gene expression profiling after PI3K/mTOR inhibition treatment was analyzed by Affymetrix microarrays.

12

Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK